Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.51 million versus the consensus estimate of $7.27 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.